Key Takeaways INCY's Monjuvi gets FDA approval for use in relapsed or refractory follicular lymphoma. The approval was backed by phase III inMIND data showing improved progression-free survival. This marks the second U.S. approval for Monjuvi in a blood cancer indication.Incyte (INCY) announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, Monjuvi (tafasitamab-cxix), for a new cancer indication.The U.S. regulatory body approved Monjuvi in combination wit ...